Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems Invests $3M in Genomica, Signs Licensing Agreement

NEW YORK, Sept 6 - Applied Biosystems (NYSE: PEB) said on Wednesday it had agreed to make a $3 million equity investment in software developer Genomica.

The companies also signed an agreement under which Genomica will license its genetic-analysis object model to Applied Biosystems.

The object model will allow Applied Biosystems to store genotyping results garnered from its various instruments in a common Oracle database. Genomica's bioinformatics software products could then be used to access the genotyping results for scientific analysis.

" The object model enhances the capability to pool data,” said Jay Rhodes, a spokesman for Applied Biosystems. “The enhanced Applied Biosystems system is what gets sold.”Rhodes declined to disclose the terms of the licensing agreement or to say what percent of Genomica’s equity Applied Biosystems will own following the deal.

A spokesperson for Genomica was not immediately available for comment.

Based in Foster City, Calif., Applied Biosystems makes instruments, reagents and software used to discover new pharmaceuticals and analyze criminal evidence.

Genomica of Boulder, Colo., develops software products used by pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. The company’s customers include AstraZeneca (NYSE: AZN), GlaxoWellcome (NYSE:GLX), and the National Cancer Institute.

Genomica and Applied Biosystems previously partnered to develop software products to be used with Applied Biosystems’ hardware.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.